Investment Analysts’ Weekly Ratings Updates for TELA Bio (TELA)

A number of firms have modified their ratings and price targets on shares of TELA Bio (NASDAQ: TELA) recently:

• 3/27/2026 – TELA Bio had its price target lowered by Citizens Jmp from $5.00 to $3.00. They now have a “market outperform” rating on the stock.
• 3/25/2026 – TELA Bio had its price target lowered by Piper Sandler from $1.25 to $1.00. They now have a “neutral” rating on the stock.
• 3/25/2026 – TELA Bio had its price target lowered by Lake Street Capital from $3.00 to $2.00. They now have a “buy” rating on the stock.
• 3/25/2026 – TELA Bio had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $2.00. They now have a “buy” rating on the stock.

TELA Bio, Inc (NASDAQ: TELA) is a commercial‐stage medical technology company headquartered in Malvern, Pennsylvania. The company is focused on developing, manufacturing and commercializing regenerative medicine and advanced soft tissue repair solutions. By integrating proprietary biomaterials and processing technologies, TELA Bio aims to offer products that support the body’s natural healing processes in wound closure, hernia repair, reconstructive surgery and other surgical specialties.

The company’s product portfolio includes acellular dermal matrices, hemostatic agents and tissue scaffold systems.